One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Effect of Helmet Noninvasive Ventilation vs High-Flow Nasal Oxygen on Days Free of Respiratory Support in Patients With COVID-19 and Moderate to Severe Hypoxemic Respiratory FailureThe HENIVOT Randomized Clinical Trial
Domenico Luca Grieco, MD1,2; Luca S. Menga, MD1,2; Melania Cesarano, MD1,2; et al
doi : 10.1001/jama.2021.4682
JAMA. 2021;325(17):1731-1743
Importance High-flow nasal oxygen is recommended as initial treatment for acute hypoxemic respiratory failure and is widely applied in patients with COVID-19.
Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory DiseasesA Randomized Clinical Trial
Silje Watterdal Syversen, MD, PhD1; Guro L?vik Goll, MD, PhD1; Kristin Kaasen J?rgensen, MD, PhD2; ?ystein Sandanger, MD, PhD3; Joseph Sexton, PhD1; Inge Christoffer Olsen, PhD4; Johanna Elin Gehin, MD5,6; David John Warren, PhD5; Marthe Kirkes?ther Brun, MD1,6; Rolf Anton Klaasen, PhD5; Lars Normann Karlsen, MD7; Geir Noraberg, MD8; Camilla Zettel, MD9; Maud Kristine Aga Ljos?, MD10; Anne Julsrud Haugen, MD, PhD11; Rune Johan Nj?lla, MD12; Trude Jannecke Bruun, MD13; Kathrine Aglen Seeberg, MD14; Brigitte Michelsen, MD, PhD15; Eldri Kveine Strand, MD16; Svanaug Skorpe, MD17; Ingrid Marianne Blomgren, MD18; Yngvill Hovde Bragnes, MD19; Christian Kvikne Dotterud, MD, PhD20; Turid Thune, MD21; Carl Magnus Ystr?m, MD22; Roald Torp, MD23; Pawel Mielnik, MD, PhD24; Cato M?rk, MD, PhD25; Tore K. Kvien, MD, PhD1,6; J?rgen Jahnsen, MD, PhD2,6; Nils Bolstad, MD, PhD5; Espen A. Haavardsholm, MD, PhD1,6
doi : 10.1001/jama.2021.4172
JAMA. 2021;325(17):1744-1754
Importance Proactive therapeutic drug monitoring (TDM), defined as individualized drug dosing based on scheduled monitoring of serum drug levels, has been proposed as an alternative to standard therapy to maximize efficacy and safety of infliximab and other biological drugs. However, whether proactive TDM improves clinical outcomes when implemented at the time of drug initiation, compared with standard therapy, remains unclear.
Effect of Half-Dose vs Stable-Dose Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Disease Flares in Patients With Rheumatoid Arthritis in RemissionThe ARCTIC REWIND Randomized Clinical Trial
Siri Lillegraven, MD, MPH, PhD1; Nina Paulshus Sundlis?ter, MD, PhD1; Anna-Birgitte Aga, MD, PhD1; Joseph Sexton, PhD1; Inge C. Olsen, PhD2; Hallvard Fremstad, MD3; Cristina Spada, MD4; Tor Magne Madland, MD, PhD5; Christian A. H?ili, MD6; Gunnstein Bakland, MD, PhD7; ?se Lexberg, MD8; Inger Johanne Widding Hansen, MD9; Inger Myrnes Hansen, MD10; Hilde Haukeland, MD11; Maud-Kristine Aga Ljos?, MD3; Ellen Moholt, RN, Msc1; Till Uhlig, MD, PhD1,12; Daniel H. Solomon, MD, MPH13; Désirée van der Heijde, MD, PhD1,14; Tore K. Kvien, MD, PhD1,12; Espen A. Haavardsholm, MD, PhD1,12
doi : 10.1001/jama.2021.4542
JAMA. 2021;325(17):1755-1764
Importance Sustained remission has become an achievable goal for patients with rheumatoid arthritis (RA) receiving conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), but how to best treat patients in clinical remission remains unclear.
Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients
Brian J. Boyarsky, MD1; William A. Werbel, MD2; Robin K. Avery, MD2; Aaron A. R. Tobian, MD, PhD3; Allan B. Massie, PhD1; Dorry L. Segev, MD, PhD1; Jacqueline M. Garonzik-Wang, MD, PhD1
doi : 10.1001/jama.2021.4385
JAMA. 2021;325(17):1784-1786
Excess Deaths From COVID-19 and Other Causes in the US, March 1, 2020, to January 2, 2021
Steven H. Woolf, MD, MPH1; Derek A. Chapman, PhD1; Roy T. Sabo, PhD2; Emily B. Zimmerman, PhD, MS, MPH1
doi : 10.1001/jama.2021.5199
JAMA. 2021;325(17):1786-1789
Trends in the Prevalence of Concussion Reported by US Adolescents, 2016-2020
Phil Veliz, PhD1; Sean Esteban McCabe, PhD1; James T. Eckner, MD, MS2; John E. Schulenberg, PhD3
doi : 10.1001/jama.2021.1538
JAMA. 2021;325(17):1789-1791
Reducing Low-Value Care and Improving Health Care Value
Allison H. Oakes, PhD1; Thomas R. Radomski, MD, MS1,2
doi : 10.1001/jama.2021.3308
JAMA. 2021;325(17):1715-1716
Evaluation of Aducanumab for Alzheimer Disease
G. Caleb Alexander, MD, MS1,2; Scott Emerson, MD, PhD3; Aaron S. Kesselheim, MD, JD, MPH4
doi : 10.1001/jama.2021.3854
JAMA. 2021;325(17):1717-1718
Revised UNAIDS/WHO Ethical Guidance for HIV Prevention Trials
Rieke van der Graaf, PhD1; Andreas Reis, MD, MSc2; Peter Godfrey-Faussett, MBBS3,4
doi : 10.1001/jama.2021.0258
JAMA. 2021;325(17):1719-1720
Respiratory Support During the COVID-19 Pandemic
Laveena Munshi, MD1; Jesse B. Hall, MD2
doi : 10.1001/jama.2021.4975
JAMA. 2021;325(17):1723-1725
Treatment Strategies for Patients With Immune-Mediated Inflammatory Diseases
Jeffrey R. Curtis, MD, MS, MPH1; Alexis Ogdie, MD, MSCE2; Michael D. George, MD, MSCE2
doi : 10.1001/jama.2021.2740
JAMA. 2021;325(17):1726-1728
Learning From Excess Pandemic Deaths
Alan M. Garber, MD, PhD1
doi : 10.1001/jama.2021.5120
JAMA. 2021;325(17):1729-1730
Diagnosis and Management of Stable Angina
Parag H. Joshi, MD, MHS1; James A. de Lemos, MD1
doi : 10.1001/jama.2021.1527
JAMA. 2021;325(17):1765-1778
Importance Nearly 10 million US adults experience stable angina, which occurs when myocardial oxygen supply does not meet demand, resulting in myocardial ischemia. Stable angina is associated with an average annual risk of 3% to 4% for myocardial infarction or death. Diagnostic tests and medical therapies for stable angina have evolved over the last decade with a better understanding of the optimal use of coronary revascularization.
The Importance of Delirium and Delirium Prevention in Older Adults During Lockdowns
Sharon K. Inouye, MD, MPH1,2
doi : 10.1001/jama.2021.2211
JAMA. 2021;325(17):1779-1780
Risk-Reducing Mastectomy
Ismail Jatoi, MD, PhD1; Zoe Kemp, MD, PhD2,3
doi : 10.1001/jama.2020.22414
JAMA. 2021;325(17):1781-1782
Pandemic Boosts an Old Idea—Bringing Acute Care to the Patient
Mary Chris Jaklevic, MSJ
doi : 10.1001/jama.2021.0127
JAMA. 2021;325(17):1706-1708
A Partnership With the Cherokee Nation Advances Medical Education on Tribal Land
Mary Chris Jaklevic, MSJ
doi : 10.1001/jama.2021.1461
JAMA. 2021;325(17):1709-1710
Experts Discuss COVID-19—Variants and Vaccine Efficacy, Immunosuppressed Patients, and More
doi : 10.1001/jama.2021.5938
JAMA. 2021;325(17):1711-1712
Cell-Based Gene Therapy Is New Option for Multiple Myeloma
Rebecca Voelker, MSJ
doi : 10.1001/jama.2021.6401
JAMA. 2021;325(17):1713
Pioneering Heart Valve Approved for Patients With CHD
Rebecca Voelker, MSJ
doi : 10.1001/jama.2021.6103
JAMA. 2021;325(17):1713
Electrical Stimulator Can Improve MS-Related Walking Problems
Rebecca Voelker, MSJ
doi : 10.1001/jama.2021.6402
JAMA. 2021;325(17):1713
Surgery for Breast Cancer Prevention
Ismail Jatoi, MD, PhD1; Zoe Kemp, MD, PhD2
doi : 10.1001/jama.2021.1647
JAMA. 2021;325(17):1804
Effect of Adjuvant Metronomic Capecitabine on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer
Feng Du, MD1; Peng Yuan, MD2
doi : 10.1001/jama.2021.2780
JAMA. 2021;325(17):1791-1792
Effect of Adjuvant Metronomic Capecitabine on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer
Deep Chakrabarti, MD1; Naseem Akhtar, MCh2; Vijay Kumar, MCh2
doi : 10.1001/jama.2021.2783
JAMA. 2021;325(17):1792-1793
Effect of Adjuvant Metronomic Capecitabine on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer—Reply
Xi-Wen Bi, MD1; Xin Hua, MD1; Zhong-Yu Yuan, MD1
doi : 10.1001/jama.2021.2786
JAMA. 2021;325(17):1793
Management of Crohn Disease
Ahmed B. Bayoumy, BSc, BPharm1; Nanne K. H. de Boer, MD, PhD2; Chris J. J. Mulder, MD, PhD2
doi : 10.1001/jama.2021.2918
JAMA. 2021;325(17):1793-1794
Management of Crohn Disease—Reply
Kelly Cushing, MD, MSCI1; Peter D. R. Higgins, MD, PhD, MSc1
doi : 10.1001/jama.2021.2921
JAMA. 2021;325(17):1794-1795
